Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
Maturitas. 2010 Apr;65(4):308-14. doi: 10.1016/j.maturitas.2010.01.012. Epub 2010 Feb 6.
Significant advances have been made in the diagnosis and treatment of female breast cancer, resulting in a decline in incidence and a global improvement in clinical outcome. The statistics for male breast cancer (MBC) stand in sharp contrast-over the past several decades, there has been a steady rise in the incidence of this disease, and clinical outcome has improved at a much slower pace. In the current review, the clinicopathologic features of MBC are described in detail. An emphasis is placed on molecular profiling of MBC, which may identify candidate biomarkers and putative targets for pharmacologic intervention. The current role of cytotoxic chemotherapy and endocrine therapy (including tamoxifen, aromatase inhibitors and GnRH analogues) is defined in the context of currently available studies. Furthermore, the potential role of targeted agents, including HER2-directed therapies, PARP inhibitors, and angiogenesis inhibitors, is delineated.
在女性乳腺癌的诊断和治疗方面已经取得了重大进展，导致发病率下降和全球临床结果的改善。男性乳腺癌（MBC）的统计数据则形成鲜明对比——在过去几十年中，这种疾病的发病率稳步上升，而临床结果的改善速度要慢得多。在本次综述中，详细描述了 MBC 的临床病理特征。重点介绍了 MBC 的分子谱分析，这可能确定候选生物标志物和潜在的药物干预靶点。在目前的研究背景下，定义了细胞毒性化疗和内分泌治疗（包括他莫昔芬、芳香酶抑制剂和 GnRH 类似物）的当前作用。此外，还描述了靶向药物的潜在作用，包括 HER2 靶向治疗、PARP 抑制剂和血管生成抑制剂。
